Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension

@article{Schwartz2010DrugIW,
  title={Drug Interactions With Phosphodiesterase-5 Inhibitors Used for the Treatment of Erectile Dysfunction or Pulmonary Hypertension},
  author={Bryan G. Schwartz and Robert A. Kloner},
  journal={Circulation},
  year={2010},
  volume={122},
  pages={88-95}
}
Sildenafil and tadalafil were the 32nd and 74th, respectively, most popular prescription drugs dispensed in the United States in 2006. Erectile dysfunction (ED) currently affects >30 million men in the United States and >150 million men worldwide and will become more prevalent as the population ages.1 Phosphodiesterase-5 (PDE5) inhibitors (PDE5Is) (sildenafil [Viagra],2 vardenafil [Levitra],3 and tadalafil [Cialis]4) are first-line therapy for ED. Use of PDE5Is will increase because sildenafil… 

Tables from this paper

THE EFFECT OF HALF-LIFE & SELECTIVITY OF PDE-5 INHIBITERS ON BLOOD HOMEOSTASIS
TLDR
Investigation of the effect of half-life and PDE-5 selectivity on biochemical changes that occur during administration of Sildanafile or Tadalafile on some hematological parameters revealed that Sildenafil produced significant alterations in Bleeding Time (IVY), fibrinogen weight, D-Dimer values and its titer after 6 weeks of starting treatment.
Adverse Events Associated With Coprescription of Phosphodiesterase Type 5 Inhibitors and Oral Organic Nitrates in Male Patients With Ischemic Heart Disease
TLDR
From 2000 to 2018, the use of PDE5 inhibitors increased 20-fold among Danish patients with IHD who were taking nitrates, and a statistically significant association between concomitant use of these medications and cardiovascular adverse events could not be identified.
Cardiac uses of phosphodiesterase-5 inhibitors.
Clinical Efficacy and Safety of Vitaros©/Virirec© (Alprostadil Cream) for the Treatment of Erectile Dysfunction
TLDR
Vitaros©/Virirec© is new topical, non-invasive treatment for ED that offers the combination of an active drug (alprostadil, a synthetic PGE1) with a skin enhancer that improves its local absorption directly at the site of action.
A New Perspective on the Nitrate–Phosphodiesterase Type 5 Inhibitor Interaction
TLDR
It is determined that the use of phosphodiesterase type 5 inhibitors with nitrates is a contraindication, with the duration between the last dose of phosphodiedterase inhibitor and nitrate use generally varying between short- and long-acting phosphodiesters, and patients receiving nitrates should be educated regarding the interaction and whether nitrate treatment can be discontinued.
Clinical use of alprostadil topical cream in patients with erectile dysfunction: a review
TLDR
Clinical trials have shown topical alprostadil cream to be effective, increasing the erectile function (EF) score of the International Index of EF by up to 13 points from baseline, and to be safe and well tolerated.
Sexual function in patients with chronic angina pectoris.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 77 REFERENCES
Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men.
TLDR
Tadalafil augmented the hypotensive effects of doxazosin but had little hemodynamic interaction with tamsulosin, and may be given for the treatment of benign prostatic hyperplasia.
Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee.
TLDR
It is possible that a precipitous reduction in blood pressure with nitrate use may occur over the initial 24 hours after a dose of Viagra, and for patients who experience an acute cardiac ischemic event and who have taken Viagra within the past 24 hours, administration of nitrates should be avoided.
Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy
TLDR
The tadalafil group showed a significantly (P<0.001) greater mean baseline to endpoint improvement on all efficacy outcome measures compared to placebo-treated patients regardless of concomitant thiazide use, and responses to tdalafil were comparable between thiazides and nonthiazide users regardless of baseline ED severity.
Hemodynamic Interaction Between a Daily Dosed Phosphodiesterase 5 Inhibitor, Tadalafil, and the α‐Adrenergic Blockers, Doxazosin and Tamsulosin, in Middle‐Aged Healthy Male Subjects
TLDR
The incidence of hypotension was low in healthy men given increasing doses of doxazosin with chronically dosed tadalafil or placebo and Administration of tadalAFil with tamsulosin was well tolerated inhealthy men.
The Clinical Pharmacokinetics of Phosphodiesterase‐5 Inhibitors for Erectile Dysfunction
TLDR
The major characteristics of the pharmacokinetic profile of all 3 PDE5 inhibitors, including bioavailability and rate of absorption, Biopharmaceutical Classification System categorization, elimination mechanisms, and metabolic profile including active metabolites are discussed.
...
1
2
3
4
5
...